MIOTENS ® - Tiocolchicoside

MIOTENS ® is a medicinal product based on Thiocolchicoside

THERAPEUTIC GROUP: Central-acting muscle relaxants.

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications MIOTENS ® - Tiocolchicoside

MIOTENS ® is used in the treatment of acute and chronic sciatica, cervico-brachial neuralgia, torticollis, post-traumatic and post-operative pain syndromes, spastic hemiparesis, Parkinson's and neurodyslectic syndrome.

Mechanism of action MIOTENS ® - Tiocolchicoside

Thiocolchicoside, active ingredient of MIOTENS ®, is a semisynthetic sulfur derivative of Colchicoside, endowed with myorelaxing activity, and therefore suitable for the treatment of syndromes also painful characterized by increased muscle tension.

Administered either intramuscularly or orally, this active ingredient is rapidly absorbed and subsequently circulated, performing its muscle relaxant action after about 1-2 hours.

However, this activity, not yet fully characterized from a molecular point of view, seems to correlate with the ability of the Thiocolchicoside to bind GABAergic and Glycineergic receptors, exerting a sensitive inhibitory action, very probably responsible for the convulsive effect of this active principle against patients to epileptic seizures.

The complex mechanism of action of this active principle therefore guarantees the performance of a muscle relaxant effect which however does not alter voluntary motility or interfere with the autonomous functions of the nervous system and in particular with the respiratory and cardiovascular system.

Studies carried out and clinical efficacy

CLINICAL EFFECTIVENESS OF TIOCOLCHICOSIDE

J Indian Med Assoc. 2008 May; 106 (5): 331-5.

Work that demonstrates the greater clinical efficacy of TIocolchicoside in determining an improvement in symptoms in patients suffering from low back pain and muscle spasm, thus guaranteeing a more rapid resumption of normal activities.

OSTEOPROTECTIVE ACTION OF TIOCOLCHICOSIDE

Br J Pharmacol. 2012 Apr; 165 (7): 2127-39. doi: 10.1111 / j.1476-5381.2011.01702.x.

Interesting experimental study that demonstrates how thiocolchicoside can suppress RANK L-induced osteoclastogenesis, thereby inhibiting bone resorption, and leading to an improvement in density.

TIOCOLCHICOSIDE AND CONVULSIONS

Seizure. 2003 Oct; 12 (7): 508-15.

Study conducted on experimental models that demonstrates the mechanisms of action of one of the collateral effects classically linked to the use of Thiocolchicoside such as convulsions, highlighting the ability of this molecule to interact with GABA receptors, antagonizing their effects.

Method of use and dosage

MIOTENS ®

Injectable solution for intramuscular use of 4 mg TIocolchicoside per ampoule.

MIOTENS ® therapy must necessarily be defined and supervised by an experienced physician, who should identify the most appropriate dosages and methods of administration for the patient.

Despite the dosage generally used is that of the 2 vials in 24 hours, the doctor should evaluate the situation from time to time based on the severity of the patient's clinical picture.

The use of this drug is contraindicated in children under 15 years of age.

Warnings MIOTENS ® - Tiocolchicoside

The administration of MIOTENS ® must necessarily be preceded by a careful medical examination aimed at clarifying the origin of the symptomatology and the consequent prescriptive appropriateness.

The particular mechanism of action of thiocolchicoside could determine the appearance of convulsions in patients subject to epileptic seizures or at high risk of convulsions.

Such evidence therefore suggests the greatest caution in administering MIOTENS ® in patients potentially at risk.

Continuous medical supervision, during treatment, is necessary in order to adapt or suspend therapy in the event of side effects worthy of clinical note.

PREGNANCY AND BREASTFEEDING

The toxic reproductive effects of thiocolchicoside, observed in experimental studies, inevitably extend the aforementioned contraindications to the use of MIOTENS ® also to pregnancy and the subsequent period of breastfeeding.

Interactions

Drug interactions worthy of clinical note are currently unknown.

Contraindications MIOTENS ® - Tiocolchicoside

The use of MIOTENS ® is contraindicated in patients suffering from flaccid paralysis, muscular hypotonia, in patients who are hypersensitive to the active substance or to one of its excipients and during pregnancy and lactation.